- Market Capitalization, $K 64,758
- Shares Outstanding, K 58,871
- Annual Sales, $ 3,050 K
- Annual Income, $ -47,060 K
- 60-Month Beta 1.92
- Price/Sales 21.05
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.2150 (-16.29%)since 08/21/20
| || |
+0.2050 (+22.78%)since 06/19/20
| || |
-0.0850 (-7.14%)since 09/20/19
The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase...
Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported a loss of $9.5 million in its second quarter.
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
--- To participate in the virtual meeting, stockholders must register by 11:59 ET on June 15, 2020 -
Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.
Infinity (INFI) delivered earnings and revenue surprises of -111.11% and 74.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Monday reported a loss of $10.9 million in its first quarter.